{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:39:22Z","timestamp":1788986362441,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10096-024-04990-w","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T11:49:27Z","timestamp":1731671367000},"page":"159-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dose optimization of piperacillin\/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in T\u00fcrkiye"],"prefix":"10.1007","volume":"44","author":[{"given":"Ecem","family":"Buyukyanbolu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Genc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Karakus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusun","family":"Comert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Otlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"4990_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijantimicag.2015.03.001","volume":"45","author":"A Potron","year":"2015","unstructured":"Potron A, Poirel L, Nordmann P (2015) Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45:568\u2013585","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"4990_CR2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1080\/14787210.2022.2071701","volume":"20","author":"Y Rafael Canton","year":"2022","unstructured":"Rafael Canton Y, Doi, Patricia J, Simner (2022) Treatment of carbapenem-resistant Pseudomonas aeruginosa infections: a case for cefiderocol. Expert Rev Anti-infective Therapy 20(8):1077\u20131094. https:\/\/doi.org\/10.1080\/14787210.2022.2071701","journal-title":"Expert Rev Anti-infective Therapy"},{"key":"4990_CR3","doi-asserted-by":"publisher","first-page":"115174","DOI":"10.1016\/j.diagmicrobio.2020.115174","volume":"99","author":"ZK \u00c7ekin","year":"2021","unstructured":"\u00c7ekin ZK, Dabos L, Malko\u00e7o\u011flu G, Fortineau N, Bayraktar B, Iorga BI, Naas T, Akta\u015f E (2021) Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. Aeruginosa high-risk clones with VIM-5\u2013 and IMP-7\u2013type carbapenemases in a tertiary hospital. Diagn Microbiol Infect Dis 99:115174","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4990_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/CMR.00040-09","volume":"22","author":"PD Lister","year":"2009","unstructured":"Lister PD, Wolter DJ, Hanson ND (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582\u2013610","journal-title":"Clin Microbiol Rev"},{"key":"4990_CR5","doi-asserted-by":"publisher","first-page":"e00535","DOI":"10.1128\/JCM.00535-19","volume":"57","author":"TE Asempa","year":"2019","unstructured":"Asempa TE, Nicolau DP, Kuti JL (2019) Carbapenem-nonsusceptible Pseudomonas aeruginosa isolates from intensive care units in the United States: a potential role for new b-lactam combination agents. J Clin Microbiol 57:e00535\u2013e00519. https:\/\/doi.org\/10.1128\/JCM.00535-19","journal-title":"J Clin Microbiol"},{"key":"4990_CR6","unstructured":"Lewis JS, Weinstein MP, Bobenchik AM, Cameau S, Cullen SK, Dingle T et al Clinical and Laboratory Standards Institute. M100: performance standards for antimicrobial susceptibility testing"},{"key":"4990_CR7","unstructured":"https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Resistance_mechanisms\/EUCAST_detection_of_resistance_mechanisms_170711.pdf"},{"issue":"2","key":"4990_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/jac\/40.2.269","volume":"40","author":"RJ Young","year":"1997","unstructured":"Young RJ et al (1997) Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 40(2):269\u2013273","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"4990_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1128\/AAC.47.6.1853-1861.2003","volume":"47","author":"VH Tam","year":"2003","unstructured":"Tam VH et al (2003) Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 47(6):1853\u20131861","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4990_CR10","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1128\/AAC.02664-14","volume":"58","author":"TW Felton","year":"2014","unstructured":"Felton TW et al (2014) Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy. Antimicrob Agents Chemother 58(7):4094\u20134102","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4990_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.diagmicrobio.2006.06.014","volume":"57","author":"CT Ong","year":"2007","unstructured":"Ong CT et al (2007) Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis 57(2):153\u2013161","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"4990_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1128\/AAC.01183-09","volume":"54","author":"JL Crandon","year":"2010","unstructured":"Crandon JL et al (2010) Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 54(3):1111\u20131116","journal-title":"Antimicrob Agents Chemother"},{"key":"4990_CR13","unstructured":"Leggett JE, Ebert ST, Fantin BR, Craig WA (1991) Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis 74(Suppl 1):179\u201384"},{"issue":"2","key":"4990_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/infdis\/159.2.281","volume":"159","author":"JE Leggett","year":"1989","unstructured":"Leggett JE et al (1989) Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159(2):281\u2013292","journal-title":"J Infect Dis"},{"issue":"2","key":"4990_CR15","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1128\/AAC.01748-12","volume":"57","author":"M Hagihara","year":"2013","unstructured":"Hagihara M, Crandon JL, Urban CM, Nicolau DP (2013) KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy. Antimicrob Agents Chemother 57(2):1086\u20131088. https:\/\/doi.org\/10.1128\/AAC.01748-12Epub 2012 Dec 17. PMID: 23254422; PMCID: PMC3553679","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"4990_CR16","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1093\/jac\/dkac232","volume":"77","author":"CM Gill","year":"2022","unstructured":"Gill CM, Oliver A, Fraile-Ribot PA, Nicolau DP (2022) In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime\/avibactam and meropenem against Pseudomonas aeruginosa. J Antimicrob Chemother 77(10):2803\u20132808. https:\/\/doi.org\/10.1093\/jac\/dkac232PMID: 35848936; PMCID: PMC9525071","journal-title":"J Antimicrob Chemother"},{"key":"4990_CR17","unstructured":"ECDC report (2023) Antimicrobial resistance surveillance in Europe.: 1-208"},{"issue":"2","key":"4990_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1099\/jmm.0.001142","volume":"69","author":"SH Lob","year":"2020","unstructured":"Lob SH et al (2020) In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples\u2013SMART Surveillance Europe 2015\u20132017. J Med Microbiol 69(2):207\u2013217","journal-title":"J Med Microbiol"},{"issue":"11","key":"4990_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01204-21","volume":"65","author":"CM Gill","year":"2021","unstructured":"Gill CM et al (2021) Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa: implications for dose optimization. Antimicrob Agents Chemother 65(11):10\u20131128","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4990_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clinthera.2022.12.004","volume":"45","author":"CM Gill","year":"2023","unstructured":"Gill CM, Nicolau DP, Global Study Group (2023) Piperacillin\/Tazobactam Dose Optimization in the setting of Piperacillin\/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: time to Reconsider Susceptible Dose Dependent. Clin Ther 45(1):72\u201377","journal-title":"Clin Ther"},{"key":"4990_CR21","doi-asserted-by":"publisher","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2021) Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis.;72(7):e169-e183. https:\/\/doi.org\/10.1093\/cid\/ciaa1478. PMID: 33106864","DOI":"10.1093\/cid\/ciaa1478"},{"issue":"3","key":"4990_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jac\/dkx427","volume":"73","author":"JW Mouton","year":"2018","unstructured":"Mouton JW et al (2018) MIC-based dose adjustment: facts and fables. J Antimicrob Chemother 73(3):564\u2013568","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"4990_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","volume":"194","author":"JA Roberts","year":"2016","unstructured":"Roberts JA et al (2016) Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med 194(6):681\u2013691","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"4990_CR24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/cid\/cis857","volume":"56","author":"ME Falagas","year":"2013","unstructured":"Falagas ME et al (2013) Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin\/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56(2):272\u2013282","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4990_CR25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/jac\/dkv288","volume":"71","author":"MH Abdul-Aziz","year":"2016","unstructured":"Abdul-Aziz MH et al (2016) Is prolonged infusion of piperacillin\/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic\/pharmacodynamic and patient outcomes? An observation from the defining antibiotic levels in intensive care unit patients (DALI) cohort. J Antimicrob Chemother 71(1):196\u2013207","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"4990_CR26","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s10096-024-04896-7","volume":"43","author":"E Buyukyanbolu","year":"2024","unstructured":"Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP (2024) Antimicrobial susceptibility profile of ceftolozane\/tazobactam, ceftazidime\/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from T\u00fcrkiye. Eur J Clin Microbiol Infect Dis 43(9):1787\u20131794. https:\/\/doi.org\/10.1007\/s10096-024-04896-7Epub 2024 Jul 12. PMID: 38995343","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04990-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04990-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04990-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T10:46:31Z","timestamp":1737024391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04990-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["4990"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04990-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,15]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human Ethics and Consent to Participate declarations: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}